NCT03336333 2026-03-09SEQUOIABeOne MedicinesPhase 3 Active not recruiting590 enrolled 12 charts 1 FDA
NCT02970318 2026-02-06A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLAcerta Pharma BVPhase 3 Active not recruiting310 enrolled 18 charts 1 FDA
NCT02048813 2025-11-28Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting529 enrolled 12 charts 2 FDA
NCT02475681 2025-08-27ElevateTNAcerta Pharma BVPhase 3 Active not recruiting535 enrolled 19 charts 1 FDA
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA